AUTHOR=Elvira David , Torres Ferran , Vives Roser , Puig Gemma , Obach Mercè , Gay Daniel , Varón Daniel , de Pando Thais , Tabernero Josep , Pontes Caridad 

TITLE=Reporting reimbursement price decisions for onco-hematology drugs in Spain

JOURNAL=Frontiers in Public Health

VOLUME=Volume 11 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1265323

DOI=10.3389/fpubh.2023.1265323

ISSN=2296-2565

ABSTRACT=The study suggests that   indicators related to the type of standard of care, references to long-lasting responders, the convenience in the use of the drug and the impact of treatment on patient’s autonomy as well as contextual indicators such as the existence of previous clinical consensus are drivers to set oncology drug prices in Spain. The implementation of MCDA-EVIDEM methodologies may be useful to capture the influence on pricing decisions of additional factors not included in legislation or consolidated assessment frameworks such as European Network for Health Technology Assessment (EunetHTA) core model. It may be opportune to consider this in the upcoming revision of the Spanish regulation for health technology assessments and pricing and reimbursement procedures.